Welcome to our dedicated page for Zealand Pharma A/S news (Ticker: ZEAL), a resource for investors and traders seeking the latest updates and insights on Zealand Pharma A/S stock.
News about Zealand Pharma A/S (Nasdaq: ZEAL) centers on its work as a biotechnology company focused on peptide-based medicines for obesity and metabolic health, as well as its collaborations, clinical data and capital markets activity. Company announcements and partner press releases highlight progress across clinical trials, strategic agreements and shareholder developments.
Readers following ZEAL news will find updates on clinical programs such as BI 456906, a dual glucagon/GLP‑1 receptor agonist co‑invented with Boehringer Ingelheim. Phase II trial results reported by Boehringer Ingelheim and Zealand Pharma showed dose‑dependent weight loss in people living with obesity or overweight and in people with type 2 diabetes, reflecting the company’s focus on metabolic pathways. News also covers scientific presentations at major meetings, where Zealand Pharma shares preclinical and clinical data on investigational peptide candidates including dapiglutide, ZP8396 and ZP6590 for potential obesity and metabolic indications.
Another recurring news theme is strategic collaboration. For example, Zealand Pharma and OTR Therapeutics announced a multi‑program strategic collaboration and license agreement to discover and develop novel therapeutics for multiple targets in metabolic diseases. Under this agreement, OTR Therapeutics leads research and preclinical development using its proprietary discovery platform, while Zealand Pharma is responsible for clinical development, regulatory submissions and global commercialization.
Investors can also track company announcements on directed share offerings, private placements, capital increases and major shareholder notifications, which explain how Zealand Pharma raises funds to support its pipeline and disclose changes in ownership stakes. For ongoing insight into ZEAL’s clinical progress, partnerships and corporate actions, this news feed aggregates relevant releases and partner communications in one place.
OTR Therapeutics and Zealand Pharma (Nasdaq: ZEAL) announced a multi-program strategic collaboration on December 11, 2025 to discover and develop oral small-molecule therapeutics for metabolic diseases.
Key commercial terms include an upfront payment of USD 20 million to OTR (potentially increasing to USD 30 million), eligibility for preclinical, development, regulatory and commercial milestone payments, a potential total consideration of ~USD 2.5 billion (majority commercial milestones), and tiered single-digit royalties on worldwide net sales. OTR will lead discovery and preclinical work; Zealand will lead clinical development, regulatory submissions, and commercialization worldwide.
Summary not available.
Zealand Pharma has announced a conference call scheduled for November 10, 2022, at 4 pm CET (10 am ET). The call will follow the release of the third quarter results for 2022. Key executives, including Adam Steensberg and Henriette Wennicke, will present insights and answer questions. Zealand Pharma specializes in peptide-based medicines, with over 10 drug candidates in clinical development. The event will be accessible via registration and will also be available as a recording on Zealand’s Investor website.
Zealand Pharma (Nasdaq: ZEAL) announced its presentations at the Obesity Society Annual Meeting in San Diego, showcasing significant clinical and preclinical research. Key highlights include data from a Phase 2 trial of the GCGR/GLP-1R dual agonist BI 456906, which showed body weight reductions of up to 9% in patients with type 2 diabetes after 16 weeks. The company will also present preclinical results on its peptide candidates, including dapiglutide, ZP8396, and ZP6590, all demonstrating potential for obesity treatment.
Zealand Pharma A/S announces its total number of shares and voting rights as of October 31, 2022, in compliance with the Danish Capital Markets Act. Following a recent increase in share capital due to a private placement of 4,975,000 new shares, Zealand now has a total of 51,513,186 shares, which equals the same number for voting rights and share capital. This reflects Zealand's ongoing focus on developing innovative peptide-based medicines, with several drug candidates advancing in clinical development.
Zealand Pharma (Nasdaq: ZEAL) received a notification from major shareholder Polar Capital on October 11, 2022. As of October 10, Polar Capital holds 5,930,317 shares, representing 11.51% of Zealand's total share capital and voting rights. Zealand Pharma is a biotechnology company focused on developing innovative peptide-based medicines, with a successful portfolio of drug candidates, including two on the market and three in late-stage development.
Zealand Pharma (Nasdaq: ZEAL) has announced a significant shareholder update on October 10, 2022. Van Herk Investments B.V. now holds 7,630,244 shares, representing 14.81% of Zealand’s total share capital and voting rights as of October 7, 2022. The announcement details the ownership structure, indicating that Van Herk Investments is ultimately controlled by Mr. Adrianus van Herk. Zealand Pharma continues to focus on developing peptide-based medicines, with multiple drug candidates in clinical development.
Zealand Pharma announced the registration of a capital increase through the issuance of 4,975,000 new shares, raising approximately DKK 786 million. Following this increase, Zealand’s share capital will reach DKK 51,513,186 with a nominal value of DKK 1 per share. The new shares will be admitted for trading on Nasdaq Copenhagen on 10 October 2022. This move aims to support the company's growth in developing innovative peptide-based medicines. The shares rank equally with existing shares concerning voting and dividend rights.
Zealand Pharma announced the completion of a directed issue and private placement of 4,975,000 new ordinary shares at a subscription price of DKK 158 each, raising approximately DKK 786 million. The offering targets institutional and professional investors and aims to support the development of Zealand's peptide-based therapeutics, particularly the Phase 3 trial of glepaglutide for Short Bowel Syndrome. The New Shares are expected to be listed on Nasdaq Copenhagen on October 10, 2022, with a 90-day lock-up period for management. The funds are projected to extend the company's cash runway until Q2 2024.
Zealand Pharma has announced the launch of a private placement of approximately 4.5 million new shares aimed at institutional and professional investors. The net proceeds will fund the ongoing development of its peptide-based therapeutics pipeline, particularly supporting the Phase 3 EASE clinical program for glepaglutide, with cash runway expected until Q2 2024. The offering is being conducted through an accelerated bookbuilding process, and the new shares are expected to be listed on Nasdaq Copenhagen by October 10, 2022.